淋巴瘤生存改善联盟（CISL）：近期成果与未来展望 - Suppr

Suppr

超能文献

The Consortium for Improving Survival of Lymphoma (CISL): recent achievements and future perspective.

作者信息

Suh Cheolwon, Park Byeong-Bae, Kim Won Seog

机构信息

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Division of Hematology/Oncology, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.

出版信息

Blood Res. 2017 Mar;52(1):3-6. doi: 10.5045/br.2017.52.1.3. Epub 2017 Mar 27.

DOI:10.5045/br.2017.52.1.3

PMID:28401092

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5383584/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e70d/5383584/54b8052f072f/br-52-3-g001.jpg

相似文献

The Consortium for Improving Survival of Lymphoma (CISL): recent achievements and future perspective.

Blood Res. 2017 Mar;52(1):3-6. doi: 10.5045/br.2017.52.1.3. Epub 2017 Mar 27.

Review of the clinical research conducted by the Consortium for Improving Survival of Lymphoma of the Korean Society of Hematology Lymphoma Working Party.

Blood Res. 2013 Sep;48(3):171-7. doi: 10.5045/br.2013.48.3.171. Epub 2013 Sep 25.

Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial.

Int J Hematol. 2018 Apr;107(4):395-404. doi: 10.1007/s12185-018-2403-9. Epub 2018 Jan 22.

Consortium for Improving Survival of Lymphoma (CISL): a model of multicenter collaboration for lymphoma studies in Korea.

Blood Res. 2015 Dec;50(4):187-8. doi: 10.5045/br.2015.50.4.187. Epub 2015 Dec 21.

Organ-specific considerations for marginal zone lymphomas in Korea, based on Consortium for Improving Survival of Lymphoma (CISL) and Korean clinical studies.

Blood Res. 2019 Mar;54(1):4-6. doi: 10.5045/br.2019.54.1.4. Epub 2019 Mar 21.

Clinical features and prognostic relevance of ovarian involvement in non-Hodgkin's lymphoma: A Consortium for Improving Survival of Lymphoma (CISL) report.

Leuk Res. 2010 Sep;34(9):1175-9. doi: 10.1016/j.leukres.2010.02.010. Epub 2010 Mar 5.

Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study.

Blood Res. 2015 Dec;50(4):242-7. doi: 10.5045/br.2015.50.4.242. Epub 2015 Dec 21.

Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study.

Cancer Commun (Lond). 2019 Oct 16;39(1):58. doi: 10.1186/s40880-019-0403-7.

Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma?: Consortium for Improving Survival of Lymphoma (CISL) study.

Int J Hematol. 2015 Oct;102(4):420-5. doi: 10.1007/s12185-015-1845-6. Epub 2015 Jul 26.

Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study.

Ann Hematol. 2012 Apr;91(4):543-51. doi: 10.1007/s00277-011-1337-6. Epub 2011 Sep 16.

引用本文的文献

Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study.

Cancer Res Treat. 2023 Oct;55(4):1355-1362. doi: 10.4143/crt.2023.271. Epub 2023 Mar 30.

Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial.

Int J Hematol. 2018 Apr;107(4):395-404. doi: 10.1007/s12185-018-2403-9. Epub 2018 Jan 22.

本文引用的文献

Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study.

Blood Res. 2015 Dec;50(4):242-7. doi: 10.5045/br.2015.50.4.242. Epub 2015 Dec 21.

Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.

Ann Hematol. 2015 Nov;94(11):1845-51. doi: 10.1007/s00277-015-2468-y. Epub 2015 Aug 8.

Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma?: Consortium for Improving Survival of Lymphoma (CISL) study.

Int J Hematol. 2015 Oct;102(4):420-5. doi: 10.1007/s12185-015-1845-6. Epub 2015 Jul 26.

Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis.

Cancer Res Treat. 2015 Apr;47(2):173-81. doi: 10.4143/crt.2014.055. Epub 2014 Oct 28.

Multicenter analysis of treatment outcomes in adult patients with lymphoblastic lymphoma who received hyper-CVAD induction followed by hematopoietic stem cell transplantation.

Ann Hematol. 2015 Apr;94(4):617-25. doi: 10.1007/s00277-014-2258-y. Epub 2014 Dec 3.

Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL).

Eur J Haematol. 2015 Jun;94(6):504-10. doi: 10.1111/ejh.12459. Epub 2014 Nov 21.

Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma.

Leuk Lymphoma. 2015 Apr;56(4):1020-6. doi: 10.3109/10428194.2014.946027. Epub 2014 Aug 20.

Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study.

Ann Hematol. 2014 Nov;93(11):1895-901. doi: 10.1007/s00277-014-2137-6. Epub 2014 Jun 20.

Clinical characteristics, pathological distribution, and prognostic factors in non-Hodgkin lymphoma of Waldeyer's ring: nationwide Korean study.

Korean J Intern Med. 2014 May;29(3):352-60. doi: 10.3904/kjim.2014.29.3.352. Epub 2014 Apr 29.

Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma.

Blood Res. 2014 Mar;49(1):15-21. doi: 10.5045/br.2014.49.1.15. Epub 2014 Mar 24.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验